NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
A phase 1/2 trial of Temozolomide in advanced solid tumours, run by Novelwise Pharmaceutical Corporation, now recruiting.
Overview
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT06012695 by Novelwise Pharmaceutical Corporation, with 79 participants planned, started 2023-08-11 and due to reach its primary completion in 2028-05-30. Interventions recorded: NBM-BMX Capsule, Temozolomide and Standard radiotherapy.
Similar pages
not linked directly; found by shared links- TrialA Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma
Shares Temozolomide, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Shares Temozolomide and the tag pipeline.
- TrialA Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Shares Temozolomide and the tag pipeline.
- TrialPh I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Shares Temozolomide and the tag pipeline.
- TrialJK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Shares Temozolomide and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.